Oncology-Focused Biotech Immuneering Jumps To Wall Street With $112M IPO

  • Immuneering Corp IMRX has kept a relatively low profile since launching with $17 million back in 2019. That is until it landed another $62 million and recruited Jefferies analyst Biren Amin as CFO earlier this year. 
  • Now, the biotech is hopping onto NASDAQ with a $112.5 million IPO. At the beginning of this month, the Company penciled in a $100 million IPO raise.
  • Immuneering offered 7.5 million shares at $15 apiece, the midpoint of a $14 to $16 range. 
  • Between $33 million and $38 million will be used to bring Immuneering’s lead candidate, a dual-MEK inhibitor dubbed IMM-1-104, into the clinic for advanced solid tumors in patients harboring RAS mutations, according to the S-1/A
  • Immuneering plans on submitting an IND for that candidate in the first quarter of 2022.
  • Another $38 million to $43 million will fund the development of other candidates in oncology and neuroscience.
  • Price Action: IMRX opened for trade at $19.50 and traded at $17.63 during the market session on the last check Friday.
Market News and Data brought to you by Benzinga APIs
Posted In: BiotechNewsHealth CareFinancingOfferingsIPOsGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!